ConductScience.org, home

Paper31228622

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin M and 16 others. J Thorac Oncol, 2019. Cited by 381 papers, by iCite.

Cite this record

ConductScience Library. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Papers, record 31228622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31228622

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
PubMed
Journal
J Thorac Oncol
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
381
iCite
Relative citation ratio, by iCite
12.5
iCite
Revised in PubMed
2020-10-01
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Offin MMichael
2Chan JMJoseph M
3Tenet MMegan
4Rizvi HAHira A
5Shen RRonglai
6Riely GJGregory J
7Rekhtman NNatasha
8Daneshbod YYahya
9Quintanal-Villalonga AAlvaro
10Penson AAlexander
11Hellmann MDMatthew D
12Arcila MEMaria E
13Ladanyi MMarc
14Pe'er DDana
15Kris MGMark G
16Rudin CMCharles M
17Yu HAHelena A

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell Transformation, NeoplasticMajor topic
MutationMajor topic
Retinoblastoma Binding ProteinsMajor topic
Small Cell Lung CarcinomaMajor topic
Tumor Suppressor Protein p53Major topic
Ubiquitin-Protein LigasesMajor topic
Adenocarcinoma of Lung
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
ErbB Receptors
Female
Follow-Up Studies
Humans
Lung Neoplasms
Male
Middle Aged
Prognosis
Protein Kinase Inhibitors
Risk Factors
Survival Rate

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R25 CA020449NCI NIH HHSUnited StatesR25CA020449PubMedNIH RePORTER
T32 CA009207NCI NIH HHSUnited StatesT32CA009207PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
UL1 TR002384NCATS NIH HHSUnited StatesUL1TR002384PubMed and NIHNIH RePORTER
P01 CA129243NCI NIH HHSUnited StatesP01CA129243PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in31558227Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep's Clothing.https://conductscience.org/library/papers/31558227

Source PubMed

Download CSV of comments and corrections

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116648503Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.J Clin Oncol2006https://conductscience.org/library/papers/16648503PubMed
216837691EGFR mutations in small-cell lung cancers in patients who have never smoked.N Engl J Med2006https://conductscience.org/library/papers/16837691PubMed
319131956Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.Nat Protoc2009https://conductscience.org/library/papers/19131956PubMed
421430269Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Sci Transl Med2011https://conductscience.org/library/papers/21430269PubMed
523470965Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Clin Cancer Res2013https://conductscience.org/library/papers/23470965PubMed
623550210Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.Sci Signal2013https://conductscience.org/library/papers/23550210PubMed
724436049Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution.Cancer Discov2014https://conductscience.org/library/papers/24436049PubMed
825122428Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.J Thorac Oncol2014https://conductscience.org/library/papers/25122428PubMed
925758528RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.Nat Commun2015https://conductscience.org/library/papers/25758528PubMed
1025801821
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
J Mol Diagn2015https://conductscience.org/library/papers/25801821PubMed
1125877892Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.Sci Transl Med2015https://conductscience.org/library/papers/25877892PubMed
1226168399Comprehensive genomic profiles of small cell lung cancer.Nature2015https://conductscience.org/library/papers/26168399PubMed
1326899170DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution.Genome Biol2016https://conductscience.org/library/papers/26899170PubMed
1427270079FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.Nucleic Acids Res2016https://conductscience.org/library/papers/27270079PubMed
1528059767Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.Science2017https://conductscience.org/library/papers/28059767PubMed
1628059768SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.Science2017https://conductscience.org/library/papers/28059768PubMed
1728336552Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Cancer Discov2017https://conductscience.org/library/papers/28336552PubMed
1828498782Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.J Clin Oncol2017https://conductscience.org/library/papers/28498782PubMed
1929151359Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/29151359PubMed
2029180607Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.Clin Cancer Res2018https://conductscience.org/library/papers/29180607PubMed

See all 27 referencesDownload CSV of references

Cited by275

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 381 citations.

PMIDTitleJournalYearIn PapersSource
42977475Transformation to Small-Cell Lung Carcinoma and Then to Sarcomatoid Carcinoma in an EGFR-Mutant Lung Adenocarcinoma Patient During Systemic Therapy: A Case Report.Thorac Cancer2026https://conductscience.org/library/papers/42977475PubMed
42973948Epigenetic regulation of cancer stem cell plasticity and relapse competence in EGFR-mutant lung cancer.Front Oncol2026https://conductscience.org/library/papers/42973948PubMed
42964587Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery.Front Pharmacol2026https://conductscience.org/library/papers/42964587PubMed
42957912Genomic landscape of EGFR-TKI resistance: from known mechanisms to unknown resistance.Cell Oncol (Dordr)2026https://conductscience.org/library/papers/42957912PubMed
42957218Long-term Disease Control After Probable Endobronchial Small-cell Transformation During Osimertinib Therapy for EGFR-mutant Lung Adenocarcinoma.In Vivo2026https://conductscience.org/library/papers/42957218PubMed
42926199Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis.BMC Cancer2026https://conductscience.org/library/papers/42926199PubMed
42900325Histologic and molecular transformation from non-small cell to small cell lung cancer: insights in the era of expanding treatment options.Med Oncol2026https://conductscience.org/library/papers/42900325PubMed
42856622Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report.Front Oncol2026https://conductscience.org/library/papers/42856622PubMed
42836273Genes, fuel, and fate in lung cancer.Biochem Soc Trans2026https://conductscience.org/library/papers/42836273PubMed
42823758Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer.BMC Cancer2026https://conductscience.org/library/papers/42823758PubMed
42816600Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nat Genet2026https://conductscience.org/library/papers/42816600PubMed
42799075Traditional Chinese medicine reprograms the tumor microenvironment to overcome EGFR-TKI resistance: mechanisms and therapeutic perspectives.Front Pharmacol2026https://conductscience.org/library/papers/42799075PubMed
42761714Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection.Front Immunol2026https://conductscience.org/library/papers/42761714PubMed
42757013Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma.Front Genet2026https://conductscience.org/library/papers/42757013PubMed
42749760Epithelial tumor suppressor deletion promotes neuroendocrine differentiation in bladder cancer and reveals homoharringtonine as a candidate vulnerability.Oncogene2026https://conductscience.org/library/papers/42749760PubMed
42724635Advanced and underlying therapeutic strategies in transformed small cell lung cancer.Front Med (Lausanne)2026https://conductscience.org/library/papers/42724635PubMed
42724630Deconvolution of evolutionary architecture unmasks a high-risk, subclonal-rich subtype in treatment-naive small cell lung cancer.J Thorac Dis2026https://conductscience.org/library/papers/42724630PubMed
42698678Long-term survival following SCLC transformation after osimertinib resistance in EGFR-mutant NSCLC: Benefit from local surgical resection and osimertinib rechallenge.Genes Dis2027https://conductscience.org/library/papers/42698678PubMed
42611544Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation.J Clin Invest2026https://conductscience.org/library/papers/42611544PubMed
42588620Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond.Cancers (Basel)2026https://conductscience.org/library/papers/42588620PubMed

See all 275 cited byDownload CSV of cited by

Genes52

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AICDA57379PubTator's text mininghttps://conductscience.org/library/genes/57379NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
AKT310000PubTator's text mininghttps://conductscience.org/library/genes/10000NCBI Gene
APOB338PubTator's text mininghttps://conductscience.org/library/genes/338NCBI Gene
AR367PubTator's text mininghttps://conductscience.org/library/genes/367NCBI Gene
ARAF369PubTator's text mininghttps://conductscience.org/library/genes/369NCBI Gene
AURKA6790PubTator's text mininghttps://conductscience.org/library/genes/6790NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CCNE1898PubTator's text mininghttps://conductscience.org/library/genes/898NCBI Gene
CDKN2A1029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene
CDKN2B1030PubTator's text mininghttps://conductscience.org/library/genes/1030NCBI Gene
CREBBP1387PubTator's text mininghttps://conductscience.org/library/genes/1387NCBI Gene
CRLF264109PubTator's text mininghttps://conductscience.org/library/genes/64109NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ELF31999PubTator's text mininghttps://conductscience.org/library/genes/1999NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FGFR12260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FGFR32261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
FGFR42264PubTator's text mininghttps://conductscience.org/library/genes/2264NCBI Gene

See all 52 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31228622

GET https://conductscience.org/api/papers/v1/31228622/references?page=2